GlassScriptPhysician profile
Nicholas J Costable
NPI 1790289197
$8,239.15
in general payments reported to CMS, 2019-2025
18 companies · $4,098 in 2025
The $4,098 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $322 · 2023: $361 · 2024: $3,457 · 2025: $4,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,192 · Travel and Lodging: $3,645 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,191.68 |
| Travel and Lodging | $3,645.05 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,641.56 | 2024-2025 | Exalt Model D, Overstitch Endoscopic Suturing System, Axios |
| Olympus America INC. | $1,098.20 | 2022-2025 | Visiglide, Endoclot Sis, Single Use Repositionable Clip |
| Ovesco Endoscopy USA, INC. | $931.69 | 2025 | |
| Abbvie INC. | $279.87 | 2022-2025 | Rinvoq, Skyrizi |
| Conmed Corporation | $275.05 | 2024-2025 | Conmed Biliary, Conmed Generators, Conmed Hemostasis |
| Gilead Sciences, INC. | $214.75 | 2022-2023 | Vemlidy |
| Takeda Pharmaceuticals U.S.A., INC. | $207.89 | 2023-2025 | Entyvio, Livtencity |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2024 | Zeposia |
| Fujifilm Healthcare Americas Corporation | $101.60 | 2024-2025 | |
| Celltrion USA INC. | $88.17 | 2024 | Vegzelma |
| Janssen Biotech, INC. | $79.99 | 2024 | Stelara |
| Medtronic, INC. | $79.18 | 2023-2024 | Nexpowder |
| Ipsen Biopharmaceuticals, INC | $31.68 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $20.34 | 2025 | |
| Aimmune Therapeutics, INC. | $19.39 | 2025 | Zenpep |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.61 | 2025 | Wegovy |
| Lilly USA, LLC | $14.81 | 2025 | Omvoh |
| Micro-Tech Endoscopy USA, INC. | $14.39 | 2025 | Eyemax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Costable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.